• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Real-world data (RWD) of the use of trifluridine/tipiracil hydrochloride (TFT) in patients with metastatic colorectal cancer: The Greater Manchester experience

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Real-world.pdf
    Size:
    75.09Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Alchawaf, A.
    Dawod, M.
    Al-Ani, M.
    Barriuso, Jorge
    Ferrera, A.
    Ho, A.
    Braun, Michael S
    Paton, Nina
    Saunders, Mark P
    Wilson, G.
    Alam, Nooreen
    Hasan, Jurjees
    Marti-Marti, F
    Kamposioras, Konstantinos
    Mullamitha, Saifee
    Show allShow less
    Affiliation
    University of Manchester / The Christie NHS Foundation Trust, Manchester
    Issue Date
    2020
    
    Metadata
    Show full item record
    Abstract
    Background Trifluridine/tipiracil hydrochloride has shown to improve progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC). Exploratory analysis suggested that patients with good prognostic characteristics GPC (18 months since first diagnosis) carry better prognosis vs. poor prognostic characteristics (PPC). We report the Greater Manchester experience of the use of TFT. Methods All consecutive patients who received TFT between August 2016 and August 2019 were included. Data were collected from electronic records. Univariate survival analysis was performed with Kaplan-Meier curve and log-rank test. Cox regression was used for multivariable analysis. Results All consecutive pts (n=188) were included; median follow up was 7.1 months. Median age was 66 IQR (59-72); 60% were male; 22% had right; 43% had left; 35% had rectal cancers. RAS mutation was identified in 29.8%. Twenty-nine (16%) received bevacizumab and 23.4% received anti-EGFR treatment. Seventy-eight (41%) had ≤ 3 sites of metastases; 134 (74%), 120 (66%) and 70 (40%) had liver, lung and peritoneal metastasis respectively; 123 (65.4%) had ≤18months since diagnosis of first metastasis, 64 patients (34%) had GPC while 122 (64.9%) had PPC. Median time from stage IV diagnosis to starting treatment was 23.9 months IQR (14.9-38.5). Thirty-six (19%) had HB < 0.001. Patients with GPC had better OS of 12.9 months (95% CI 10.11-15.77) compared to 7.45 months in patients with PPC (95% CI 10.1 to 15.7), p< 0.001. Patients with liver metastasis had a shorter median PFS 2.7 months and OS 7.5 months (95% CI 6.3-8.8) when compared with patients with no liver metastasis with PFS 4.3 months (95% CI: 2.5 to 2.9), p=0.002 and OS of 12 months (95% CI: 9.3-14.7), p=0.001. Patients who were in the GPC group and had no liver metastasis had an improved median OS of 13.9 months when compared with the rest of patients in whom median OS was 7.8 (95% CI 7.2 to 20.7), p=0.002. Multivariable analysis showed that GPC was an independent prognostic factors for OS (HR 0.582; 95% CI 0.3-0.8; p=0.005). Grade 3 neutropenia was an independent prognostic factor for PFS (HR 0.55; 95% CI 0.39-0.79; p=0.001) and OS (HR0.4; 95% CI 0.2-0.6; P< 0.001). Conclusion Our RWD on TFT was associated with a better OS than expected. This RWD study was able to validate GPC, GPC with no liver metastases and grade ≥ 3 neutropenia as subgroups benefiting the most from TFT.
    Citation
    Alchawaf A, Dawod M, Al-Ani M, Barriuso J, Ferrera A, Ho A, et al. P-339 Real-world data (RWD) of the use of trifluridine/tipiracil hydrochloride (TFT) in patients with metastatic colorectal cancer: The Greater Manchester experience. Annals of Oncology. 2020;31:S200.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/623321
    DOI
    10.1016/j.annonc.2020.04.421
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2020.04.421
    Type
    Meetings and Proceedings
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2020.04.421
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.